A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation +/- Taxotere (Docetaxel) for Non-metastatic Prostate Cancer Patients With a Rising PSA
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Docetaxel (Primary) ; Bicalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Aug 2018 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 06 Aug 2018 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.